Australian biosimilar developer NeuClone has announced that it is developing a proposed biosimilar denosumab (referenced on Amgen’s Prolia, Xgeva).
Australian biosimilar developer NeuClone has announced that it is developing a proposed biosimilar denosumab (referenced on Amgen’s Prolia, Xgeva). Denosumab, a RANK ligand inhibitor, is used in the treatment of osteoporosis, as well as treatment-induced bone loss, among other indications. The proposed denosumab molecule brings NeuClone’s biosimilar pipeline to 5 products (it is also developing biosimilars to trastuzumab, ustekinumab, adalimumab, and palivizumab).
In a statement, NeuClone’s CEO, Noelle Sunstrom, PhD, said of the early-stage development of this drug, "We are dedicated to broaden[ing] patient access to biological medicines globally by making affordable products of the highest quality. At all stages of development, we are focused on global approval from the most stringent regulatory bodies including the US and European agencies."
The statement went on to describe its product as a potential “early market entrant” for denosumab biosimilars. If eventually approved, NeuClone’s product would compete for a share of substantial sales; Amgen earned $3.5 billion from the branded drug in 2016, and NeuClone predicts that global sales of the treatment could reach $5.6 billion by 2022.
Other biosimilar developers aiming for a share of the denosumab market include AryoGen Pharmed, which is currently recruiting participants in a phase 3 study of its proposed biosimilar in patients with osteoporosis, and BioXpress Therapeutics, which reports that denosumab is a “future product” for development.
Meanwhile, Amgen, maker of the reference denosumab, has secured a new indication for its innovation. The FDA last week approved the drug maker’s supplemental Biologics License Application (sBLA) for the reference drug to expand the approved indication for the prevention of skeletal-related events to include patients who have multiple myeloma (MM). The approval of the sBLA was based on data from a phase 3 study conducted in 1718 patients. The study met its primary endpoint of demonstrating the noninferiority of denosumab to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with MM.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.